[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":40,"_57":40,"_58":59,"_60":61,"_62":63},"id","b66wsr94wz87xf9ojzimz2opc","revision",2,"title","UroGen Pharma 公布截至 9 月 30 日季度财务业绩","originalTitle","UroGen Pharma Ltd. (0001668243) (Filer)","summary","UroGen Pharma 于 11 月 4 日公布截至 9 月 30 日季度的财务业绩，并提交 Form 8-K 当前报告。报告将相关业绩新闻稿作为附件 99.1 提供；文件未列出具体财务数据。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":40,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-11-04T13:08:03.000Z","discoveredAt","2026-11-04T13:36:39.092Z","timelineAt","category","ai-products","tags",[81,82,83],"stockSymbols",[80],"score",24,"selected",true,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":61},"outline",[],"relatedStories",[75],"indexable","markdownAvailable","group",{"_64":65,"_43":66,"_67":14,"_68":69,"_70":71},"hasTranslation",false,"bodyLanguage","original","factId","f5_HhIH49oZE",{"_72":73,"_15":74},"reportCount","additionalSourceCount",1,"developmentCount",0,"publicId","2aab379a-b910-450f-8978-4f80dae3a9cf","UroGen公布第三季度业绩，ZUSDURI收入增长",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2026

UROGEN PHARMA LTD.

(Exact name of registrant as specified in its charter)

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

Israel

\n\t\t\t

001-38079

\n\t\t\t

98-1460746

\n\t\t\t

(State or other jurisdiction

\n\n\t\t\t

of incorporation)

\n\t\t\t

(Commission

\n\n\t\t\t

File Number)

\n\t\t\t

(IRS Employer

\n\n\t\t\t

Identification No.)

\n\t\t\t

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

400 Alexander Park Drive, 4th Floor

\n\n\t\t\t

Princeton, New Jersey

\n\t\t\t

08540

\n\t\t\t

(Address of principal executive offices)

\n\t\t\t

(Zip Code)

\n\t\t\t

Registrant’s telephone number, including area code: +1 (646) 768-9780

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

☐

\n\t\t\t

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

\n\t\t\t

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

☐

\n\t\t\t

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

\n\t\t\t

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

☐

\n\t\t\t

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

\n\t\t\t

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

☐

\n\t\t\t

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

\n\t\t\t

Securities registered pursuant to Section 12(b) of the Act:

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

Title of each class

\n\t\t\t

Trading

\n\n\t\t\t

Symbol(s)

\n\t\t\t

Name of each exchange

\n\n\t\t\t

on which registered

\n\t\t\t

Ordinary Shares, par value NIS 0.01 per share

\n\t\t\t

URGN

\n\t\t\t

The Nasdaq Stock Market LLC

\n\t\t\t

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

Item 2.02

\n\t\t\t

Results of Operations and Financial Condition

\n\t\t\t

On November 4, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

Item 9.01

\n\t\t\t

Financial Statements and Exhibits.

\n\t\t\t

(d)

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t Exhibit \n\n\t\t\t Number \n\t\t\t		\n\t\t\t Description \n\t\t\t

\n\t\t\t 99.1 \n\t\t\t		\n\t\t\t Press Release dated November 4, 2026 \n\t\t\t

\n\t\t\t 104 \n\t\t\t		\n\t\t\t Cover Page Interactive Data File (embedded within the Inline XBRL document). \n\t\t\t

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t Date: November 4, 2026 \n\t\t\t	\n\t\t\t UROGEN PHARMA LTD. \n\t\t\t


	\n\t\t\t By: \n\t\t\t	\n\t\t\t /s/ Chris Degnan \n\t\t\t
		\n\t\t\t Chris Degnan \n\t\t\t
		\n\t\t\t Chief Financial Officer \n\t\t\t

","zhKind","complete","URGN","公司与财报","财报","Nasdaq","aihot","/items/b66wsr94wz87xf9ojzimz2opc","https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/0001437749-26-034769-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1794960000&sig=44baa70fbeef50e6","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1794960000&sig=a4957e0f65b84b31 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1794960000&sig=c50e8e83f0dcfb02 96w","changelogVersion","2026-10-01T08:00"]